Skip to content
MARKETS / BALCAO / HYEX
BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP

Healthy Extracts Inc. HYEX

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$4.5M
▲ 44.9% YoY
$-881,119
In brief

What this company does

We are a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals. Our proprietary and patented products target select high-growth categories within the multibillion-dollar nutraceuticals market, such as heart, brain and immune health. Guided by this mission, our first two acquisitions (in 2019 and 2020, respectively) formed our historical operating subsidiaries, Bergamet NA, LLC (“Bergamet”), which offers nutraceutical heart and immune health products, and Ultimate Brain Nutrients, LLC (“UBN”), which offers nutraceutical products for brain health. Our mission is to acquire or create products with health and performance benefits that have mass consumer appeal. We compete with other manufacturers, distributors and marketers of vitamins, minerals, herbs, and other nutritional supplements both within and outside the U.S.

Written from the business description in Healthy Extracts Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 9 April 2026. Every sentence was checked against that document before publication.

Growth
USD 4.5M
Revenue, FY2025 · full 11-year series below
Revenue $M Net income $M
FY2025 · Revenue 4.5 · Net income -0.9
2M4M-2M201520172019202120232025
Compound annual growth
+26.1%
+28.3%
+44.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +28.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−20 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating — · Net -19.5%
-20000%-40000%201520172019202120232025
ROE
FY2025 · ROE -7.2%
-200%-400%201520172019202120232025

Each USD of equity lost 7 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -0.4
-0.8M-1.6M201520172019202120232025

Total assetsUSD 27.8M
EquityUSD 24.0M
CashUSD 146,935.00
Current ratio0.79×

Equity funds 86% of total assets.

The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015
Revenue $B0.00.00.00.00.00.00.00.00.00.00.0
Operating income $B·······−0.0−0.0−0.0−0.0
EBITDA $B·······−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.0·······
Net income $B−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0
Free cash flow $B··−0.0−0.0−0.0·−0.0····
EPS, diluted $·····−0.010.01−1.21−15.82−0.21−0.05
Dividend / sh $···········
Payout %···········
ROE %−7.2−123.2−175.0−45.3−74.6−259.2····−562.3
Shares out B0.020.000.000.000.340.310.120.000.000.020.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 49 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 45 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityMedicinal Chemicals & Botanical Products
Listed onOTC market
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2015

Share this section

Download image